Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

---

Background and purpose: Breast cancer is one of the leading causes of death in women around the world with a very high degree of mortality and morbidity. Conventional treatments use cytotoxic drugs which have high levels of side effects, affecting the patient’s quality of life. Therefore today’s pharmacology is looking into treatments with low side effects and maximum efficiency. The helicobacter pylori neutrophil-activating protein (HP-NAP) is a virulence factor that attracts and activates neutrophils, and promotes their endothelial adhesion and the production of oxygen radicals and chemokines. HP-NAP is an immune modulator able to induce the expression of IL-12 and IL-23. Chitosan is biodegradable and biocompatible component. It is low toxicity effect, so apply in drug delivery targets. In this study, we evaluated the preparation of chitosan nanoparticles carrying recombinant HP-NAP helicobacter pylori. Materials and methods: Chitosan nanoparticles were produce. The size and morphology of the nanoparticles were investigated. Recombinant HP-NAP helicobacter pylori were produce. Results: SDS-PAGE analysis showed the expression of an approximately 20,000 Dalton protein. DLS confirm size and zeta potential of the nanoparticle. Conclusion: The complex has the potential to shift antigen-specific T-cell responses from a predominant Th2 to a polarized Th1 cytotoxic phenotype, characterized by high levels of interferon-γ and tumor necrosis factor-a production. HP-NAP may be a new tool for future therapeutic strategies aimed in cancer immunotherapy. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells.

Keywords: Cancer, recombinant helicobacter pylori neutrophil-activating protein (HP-NAP), chitosan

Full-Text [PDF 988 kb]   (3555 Downloads)    

Add your comments about this article : Your username or Email:

---

---